Non-compliance or sub-optimal treatment adherence affects up to 80% of people with psychosis (Corrigan et al, 1990) , and investigating measures to counteract it has been designated a research priority by the National Health Service. The Royal Pharmaceutical Society of Great Britain (1997) have recently called for the development of major research, training and educational initiatives to promote awareness of a revised model of compliance behaviour, namely 'concordance'. It underlines the importance of the treatment alliance and patient participation. A new intervention based on motivational interviewing and cognitive approaches to psychotic symptoms, namely compliance therapy, fits well with these principles. The intervention was tested in a pilot study (Hayward et al, 1995) and we have reported encouraging six-month outcome results from a randomised controlled trial of this intervention (Kemp et al, 1 9 9 6~) .
The content of the intervention is described in detail elsewhere (Kemp et al, 19966) and is summarised below. This paper reports the 18-month follow-up results of the trial with an extended sample and includes data on community tenure following discharge from hospital.
Table I Characteristics of sample (n=74)
The study population was drawn from consecutive acute admissions with DSM-111-R (American Psychiatric Association, 1987) diagnosed psychotic disorders aged 18-65 over a 14-month period to a ward of the Maudsley Hospital serving an inner London catchment area.
Non-English speakers, patients with significant learning disabilities, deafness or organic brain diseases were excluded.
There were 105 eligible people from whom consent to enter the trial was sought. Patients were assessed within one week of admission, or, in a few cases, after a period on an intensive care unit. There was a 30% non-participation rate, due to refusal (n=16) or rapid discharge (n=15). Table 1 shows the characteristics of the remaining subjects who were a mixed group of 74 people with psychotic disorders, the majority with schizophrenia according to DSM-111-R criteria (ascertained following chart review and clinical interview). Of the remainder, most had mood disorders. There were no significant socio-demographic differences between compliance therapy treatment and control groups at inception. This extended sample has a similar composition to the original sample of 47 subjects reported (Kemp et al, 1996a ) with no significant difference in age, chronicity, gender, ethnicity, detention status and proportion with schizophrenia. Most of the subjects in our present study were suffering a relapse. All were receiving neuroleptic drugs. After detailed description of the study to the subjects, written informed consent was obtained.
Compliance therapy Control group
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Design
Patients were randomly assigned to the intervention consisting of 4-6 sessions (mean=4.7) of compliance therapy, lasting 20-60 minutes, approximately twice weekly, or the control treatment consisting of an equal number (mean=4.5) of sessions of supportive counselling (t=1.36, NS). The average total time spent with each patient by the investigators was 3-3.5 hours. In the control condition, patients could present any concerns or issues for discussion, but when medication issues were broached, they were directed to discuss such issues with their treating teams. Both treatments were additional to routine management while in-patients (which included appropriate education and discussions about treatment on an informal basis by the treating teams). After discharge from hospital, all subjects received routine after-care as determined by their responsible clinical teams. Booster sessions of compliance therapy or non-specific counselling were offered at 3, 6 and 12 months.
Intervention
Four to six sessions of compliance therapy were given, divided into the following three phases.
Phase I
The patient's illness history was reviewed, to ascertain his or her conceptualisation of the illness and stance towards treatment.
Where applicable an attempt was made to link medication cessation with relapse. Negative treatment experiences were acknowledged. Denial of illness or need for treatment was met with gentle enquiry into the ensuing social consequences or lifestyle disruption.
Phose 2
Ambivalence towards treatment was explored further. The therapist openly predicted certain common misgivings about treatment (Goldstein, 1992) , such as fears of addiction, loss of control, loss of personality. Sometimes patients confuse symptoms and side-effects and misconceptions can be corrected. The natural tendency to stop medication when one feels well was discussed, and the meaning attached to medication was explored, that is identity as a 'sick person'. The patient was invited to weigh up the benefits and drawbacks of treatment, and the therapist 'homed in' on the benefits, especially when they emerged spontaneously. Symptoms reported by the patient were fed back as symptoms for treatment. Indirect benefits of medication were highlighted (e.g. getting on better with people). Metaphors were used, such as medication as a 'protective layer'. The therapist aimed to create a degree of cognitive dissonance in the patient, that is that poor compliance is actually disadvantageous for that individual in terms of his or her needs, lifestyle and goals.
Phose 3
Normalising rationales were used to deal with stigma. Analogies with physical illness requiring maintenance treatment were suggested, and the prevalence of illness was highlighted with examples of famous sufferers. The use of medication is reframed as a freely chosen strategy to enhance quality of life. The metaphor of medication as an 'insurance policy' to stay well (Falloon, 1984) was used. The therapist stressed the importance of staying well in order to reach certain self-identified goals and maintaining valued sources of fulfilment. The consequences of stopping medication were predicted, and characteristic prodromal symptoms identified, when early intervention could prevent a full-blown episode.
The therapy was given principally by R.K., with a minority seen by P.H. The therapists were trained in cognitive-behavioural psychotherapy, and attended a workshop on motivational interviewing. Regular supervision was undertaken to ensure consistency with regard to the delivery of the intervention.
Assessment instruments
Prior to the intervention, all patients received a thorough clinical evaluation and also an assessment battery, which included the following: (a) Brief Psychiatric Rating Scale (BPRS; Lukoff et al, 1996) a semi-structured interview for the major psychiatric symptoms (range 24168).
(b) Global Assessment of Functioning Scale (GAF disability scale; from DSM-111-R; American Psychiatric Association, 1987; range from 0-100 with 10 defined anchor points relating to social competence). & Knapp, 1992) , a measure of service utilisation. The CSRI data are reported in a companion paper.
Outcome assessments
All ratings were repeated prior to discharge, post-treatment. At three-months, social functioning was evaluated using the GAF scale (disability). A composite compliance measure was obtained using the seven-point scale, based on corroboration from as many sources as possible including relatives, the out-patient clinic psychiatrist, the community psychiatric nurse and the family practitioner (mean number of sources approximately two). These evaluations were all repeated at six month, 12-month and 18-month follow-up with the addition of a seven-item abridged BPRS (including the main psychosis, negative symptom and depression items), the insight measure SAI and the self-report treatment attitudes scale, DAI. Initial, immediate post-treatment ratings, and half the three month assessments were made by R.K. All the remaining follow-up evaluations were carried out by an independent assessor who was blind to treatment status. Satisfactory interrater reliability was established by repeated joint ratings for BPRS, GAF, SAI and AMQ (intra-class coefficients 0.75-0.90).
Statistical analysis
Sample characteristics were analysed using t-test or odds ratios to check the randomisation. Baseline measures for the two groups were compared using t-tests. There are a variety of methods for analysing longitudinal data as collected during this study (Everitt, 1995) . Most reported analysis in the psychiatric literature have involved the use of univariate or multivariate analysis of variance of the repeated measures with 'time' being assumed to be the within subject factor. Such methods may be acceptable when the data contain no (or very few) missing values but when applied to complete-cases only in studies where there are a substantial number of drop-outs they are very poor. (In fact, they are not particularly appropriate even when the data are complete.)
Here, because of the number of missing values, an alternative procedure was used in which both the mean profiles of the treatment groups over time and the covariance structure of the repeated measurements are modelled and estimates of model parameters and their standard errors obtained by the method of maximum likelihood. Covariates including baseline measures can be easily incorporated into such models. (For full details see Diggle et al, 1994) . This approach makes maximum use of the data available, so that the observations made on patients who eventually drop-out are used in the analysis. The method is implemented in the BMDP SV programme and in SAS Proc Mixed. A crucial assumption behind the models used is that the missing values are non-informative. (This assumption also applies to the ANOVA and MANOVA procedures often applied to complete case analysis in the psychiatric literature, although in most accounts of using these methods this is generally ignored.) Drop-out is noninformative when the probability of dropping out does not depend on the unrecorded values of the outcome variable that would have been observed had the individual remained in the study. (A technical account of the difference between informative and non-informative missing values is given in Diggle et al, 1994 and Diggle & Kenward, 1994.) Possible procedures for testing for informative missing values and analysing data containing such values are described in Diggle & Kenward (1994) . Unfortunately, there is currently no generally available software for applying these procedures. Evidence exists (Diggle & Kenward, 1994) that the biases introduced by the analysis used here are often small, even when dropouts are informative, making the modelling procedure adopted here likely to be the best method routinely available. Certainly, other methods of dealing with drop-outs in longitudinal studies, for example, complete case analysis or last observation carried forward, will be even less satisfactory in the presence of informative drop-outs, or indeed when the observations are simply missing at random (Everitt, 1998) .
After initial exploration of models including all the covariates of interest and treatment group x time effects with varying covariance structures, a final model was determined for each outcome measure. The covariates included for possible inclusion were treatment group, age, gender, IQ, ethnicity, diagnosis, first admission status, chronicity, detention status and extrapyramidal side-effects.
Finally, an analysis of length of time to readmission was performed using Cox's regression (Cox, 1972) , allowing for 'censored' observations, that is patients not readmitted during the 18-month follow-up. Covariates included demographic characteristics and baseline measures on each of the response variables.
RESULTS

Baseline measures
The comparison of clinical variables between the intervention and control groups are shown in Table 2 . Prior to the intervention, the two groups had similar scores on the BPRS, 59.6 (s.d. 14.9) in the intervention group, and 55.7 (s.d. 13.6) in the control group (t=1.17, P=0.24), and were receiving similar neuroleptic doses (869 mg u. 776 mg respectively, in chlorpromazine equivalents; t=0.57, P=O.S7). Twelve patients in the intervention group and 14 patients in the control group were receiving intramuscular depot antipsychotics. A similar proportion in each group were also receiving lithium, carbamazepine or antidepressants, 14 in the intervention group and 11 in the control group. There were no significant differences in mean baseline scores on insight, attitudes to medication, and compliance ratings -the latter was 3.7 for the intervention group u. 4.1 for the control group (t=1.52, P=0.13), indicating rather poor initial compliance.
Attrition
Ten subjects were lost during the first six months of follow-up, five from each group, though in some cases it was possible to rate functioning and compliance based on information from community mental health professionals or the family practitioner.
Subsequently, a further 14 could not be directly re-interviewed at 12-month followup, though again additional ratings were obtained from other sources. Time constraints allowed only 12-month follow-up in six cases. Post-treatment drop-out occurred due to refusal ( l l ) , patients either being uncontactable (7) or moving out of the area (2) or recovered patients who were working or at college and no longer having psychiatric out-patient treatment (2). One patient was in prison during most of the follow-up period. At each time point, several patients failed to attend appointments for follow-up interview, did not complete the full battery of assessments, or failed to return self-report measures. There were two deaths, one resulting from stroke in a 65-year-old man with hypertension, and one from myocardial infarction in a 40-year-old man who was overweight and a heavy drinker and heavy smoker. Another 59-year-old man suffered a severe stroke with hemiplegia and aphasia, requiring total nursing care. There were no suicides.
Overall, 35% were lost during the follow-up period (11 (28%) from the compliance therapy group and 15 from the control group (43%), x2=1.73, NS). The posttreatment drop-outs did not differ from the patients who completed the follow-up on any demographic characteristics (age, gender, chronicity, previous number of admissions, ethnicity, schizophrenia diagnosis, detention under the Mental Health Act).
However, the drop-outs had lower baseline insight ratings (28.9% u. 42.3%; t=2.33, P < 0.05) and more severe extrapyramidal side-effects at baseline (7.2 u. 3.8; t=3.55, P<0.01). There was no difference in their baseline BPRS ratings. 
Repeated measures
Compliance and this advantage was maintained at a
The estimates for the parameters in each of A significant effect was found for compliconstant level over all post-intervention the derived models, together with their ance therapy treatment, but not for time, assessments (95% CI 0.9-1.6). This standard errors are available from the and no significant treatment groupx time equates to a mean difference of 19% author upon request. The baseline scores interaction was found. Thus there was a (between one and two points on the were positively related to the outcome significant advantage for the compliance observer-rated compliance scale) between scores for each variable.
therapy group immediately post-treatment the two groups.
Insight
For the insight scale SAI-E, there was a significant advantage for the compliance therapy group (95% CI 12.3-25.2%), but there was no significant time effect, and no significant treatment group by time interaction. Therefore, patients who received compliance therapy had significantly greater insight post-treatment and retained this over the follow-up period, with a mean difference of 18.8% on the insight scale.
Drug attitudes
The DAI scores showed an advantage following compliance therapy treatment (95% CI 2.5-7.2). Again there was no effect of time, and no treatment group by time interaction. Thus the compliance therapy group had more favourable scores immediately post-treatment and this advantage was retained over all post-intervention assessments, with a mean difference of 15.6% on the drug attitudes inventory. Similarly, the AMQ results showed a significant advantage for the compliance therapy treatment group at post-treatment (95% C12.1-6.0).
Global functioning
For GAF scores there was a significant effect for compliance therapy treatment, time and a significant treatment group by time interaction. This indicated a linear change over time different for the two groups so that the intervention group improved relatively more over time.
Symptoms
Both groups improved significantly in their BPRS total scores, from pre-to post-treatment. The final model for the seven-item abbreviated BPRS over the 18-month follow-up showed a non-linear time effect (a quadratic change over time, with no difference between the intervention and control group). Subgroup analyses revealed the following: patients with schizophrenia tended to have a less favourable outcome in terms of social functioning (95% CI 7.9-14.8), symptom level (95% CI 2.6-53, insight (95% CI 9.4-22.7) and treatment attitudes (95% CI 1.3-6.1). The following effects were marginally significant: patients who were formally detained under the Mental Health Act tended to have lower compliance outcome scores (95% CI 0.01-0.80), as did patients with more severe baseline extrapyramidal side-effect scores; patients undergoing first admissions tended to have lower mean outcome compliance scores than readmissions (95% CI 0.5-1.4), and there was a tendency for non-White patients to have better global functioning outcome scores than White patients (95% CI 0.04-6.5).
hospital over the follow-up period (mean (s.d.) days: compliance therapy group 41.7 (75.5); control group 61.6 (90.8); MannWhitney U 571.5, z= -1.26, P=0.208).
DISCUSSION
Community tenure and readmission
The survival analysis results show that the compliance therapy group had a significant advantage in terms of survival of community tenure (time to readmission) over the 18-month follow-up period (see Fig. 1 ). A Cox's regression analysis on survival time to readmission (with compliance therapy treatment=l, control treatment=2) produced a regression coefficient of 0.79 for the compliance treatment (SE=0.32, z=2.52). Exponentiating this value, the hazard function (for risk of readmission) of a person in the control group was 2.2 times that of a person in the compliance therapy group (approximate CI 1.16-4.1 8).
In terms of a percentage increase, this corresponds to the control group having a 120% increase in hazard function (CI 16-318%). The regression analysis also showed a significant effect of baseline global functioning on the outcome survival to readmission. In terms of percentages, raising GAF by one unit results in a 5% decrease in hazard (CI 2-9%).
There was no significant different between the compliance therapy group and the control group in overall time spent in Time to readmission (days) A weakness of the study is the drop-out rate over follow-up; the statistical method used to deal with the subsequent missing values has already been discussed. A high rate of patient refusal and drop-out would not be unexpected with this relatively unselected and highly disturbed patient sample, of which 59.5% were admitted involuntarily. In fact, the actual initial refusal rate was IS%, and subsequent attrition by one-third included only 11 overt refusers. The therapy sessions were very well accepted by patients, with all those recruited completing the course of therapy. Substantial follow-up drop-out rates have been reported in: (a) drug studies; (b) prospective studies of inner-city samples where at least 10% relocate beyond catchment area boundaries each year; and (c) studies of psychosocial interventions in similar populations (Tarrier et al, 1993) . Longer followup periods inevitably lead to greater attrition. A practical issue is that of tracking subjects for follow-up in a highly mobile inner-city sample.
Measuring compliance
Another methodological issue concerns the measure of compliance. This was an indirect composite measure based on information from a number of sources, which correlated strongly at each time point with measures of treatment attitudes, lending it concurrent validity. A mean advantage for the compliance therapy group of between one and two points on the observer-rated compliance scale is a clinically meaningful difference (for example it could amount to the difference between a patient with a bipolar disorder accepting lithium with some supervision rather than being reluctantly maintained on a less appropriate depot medication schedule). However, it may be argued that lack of a direct compliance measure is a weakness in this study, though all these measures have their drawbacks. Pill counts have been widely used in the past even though despite the well-recognised potential for inaccuracy (Rudd, 1976; Kane, 1983; Pullar et a[, 1989 ). Furthermore, they are time-consuming, demanding of manpower, and ultimately not particularly suitable for: (a) in-patient studies where medication is largely administered by staff; (b) studies involving patients on depot medication; (c) patients with individually tailored regimes. Serum assays are expensive, invasive and are not available for the full range of antipsychotics; we believe their use in this study would have further adversely affected the drop-out rate.
Urine tests for a drug or its metabolite may overestimate compliance with drugs like antipsychotics with a long half-life (Churchill, 1985) ; also currently available assays may not detect some antipsychotics at the lower dose range. Both serum and urine assays are of limited value in assessing partial compliance (Babiker, 1986) . While simple self-report compliance measures are poorly predictive of behaviour, Hogan et a1 (1983) found that DAI ratings could accurately assign 89% of a large out-patient sample to compliant and non-compliant groupings.
Observer bias
Observer bias was another potential problem. The initial ratings and most of the three-month follow-up ratings of functioning and compliance were made by the research psychiatrist (R.K.) who was not blind to treatment status, though the compliance ratings were based on information from impartial sources including community psychiatric nurses and out-patient doctors on the clinical teams. However, all six-month, 12-month and 18-month ratings on the other hand were carried out by two researchers trained in their use, who were blind to treatment status. Inspection of the results shows consistency between ratings over the serial points, and satisfactory interrater reliability coefficients were obtained. Despite these shortcomings, the findings suggest that compliance therapy does have a measurable and positive effect on treatment adherence.
Implications
The past few years has witnessed the application of several cognitive-behavioural techniques to the field of psychosis (Tarrier et al, 1993; Garety et al, 1994; Drury et a/, 1996) . Our approach sought to tackle the wider problem of poor treatment adherence in patients with acute psychotic disorders. It is not possible to discern whether specific ingredients of the intervention were critical to its effectiveness; further controlled studies comparing compliance therapy with other cognitive-behavioural approaches would be illuminating in this regard. Compliance covers much of what would be regarded as good practice; however, this does not negate the value of investigating its systematic application, from an evidence-based medicine perspective. There was no significant difference between the groups on degree of symptomatology on an abbreviated sevenitem BPRS comprising the main psychotic symptoms (as well as 'negative' symptom items which are considered to be less responsive to medication), but a delayed advantage for the intervention group was found for overall global social functioning. It is difficult to account for the lack of a clear advantage for core psychotic symptoms, arguably the point of better treatment concordance.
It is possible that a significant difference might have emerged from a more comprehensive symptom assessment during followup, especially as there was a significant advantage for the compliance therapy group in outcome functioning ratings. Second, it remains plausible that many of the severely ill patients with psychosis in the present study remain symptomatic despite medication, while at the same time showing a benefit from treatment in their global functioning. Importantly, no suicides occurred during the study; this is despite the improvements in insight achieved, and the reported link between suicidality and insight, albeit with an alternative insight measure (Amador et a/, 1996) . It should be noted that the compliance therapy package includes components designed to protect self-esteem, though this was not measured.
Readmission, outcome and survival in the community
There was a high readmission rate in the sample overall, but this must be interpreted in the light of minimal selection criteria, high morbidity, and high levels of social deprivation in our patient population. It is disappointing that the overall number of patients who were readmitted did not differ significantly between the two groups. However, survival in the community before relapse was substantially improved in the group receiving compliance therapy.
The study lacks statistical power but the effect size (for chances of avoiding readmission in the 18 months following an acute psychotic episode if given compliance therapy) suggests the potential impact of the results if replicated in a larger sample. Exploratory analyses including covariates suggested worst outcome overall for patients with a schizophrenia diagnosis. These findings must be considered tentative given the problems attempting a subgroup analysis with a small sample size. Other authors have suggested that among psychotic disorders in general, patients with schizophrenia are particularly prone to poor insight (Amador et al, 1994) . The finding concerning first-admission patients could relate to acuteness of onset, lack of previous experience of the effectiveness of neuroleptic drugs, or perhaps denial of the need for treatment which some view as a typical or adaptive phase-appropriate response, protecting self-esteem (McCorry ef al, 1995) . Previous work suggests that poor compliance may be associated with more severe drug side-effects; our results support this (for extrapyramidal side-effects, specifically). Extrapyramidal side-effects tended to increase drop-out, arguably a manifestation of generally poor compliance.
Compliance therapy, unlike the more labour-intensive interventions previously cited, is eminently adaptable to the typical busy clinical setting, and we have found it to be very acceptable to patients.
The emphasis on the patient's unique experience of treatment accords well with current national initiatives towards concepts of 'concordance' or partnership in treatment. We suggest that the combination of cognitive psychoeducational approaches like compliance therapy with adequate and effective pharmacotherapy and appropriate psychosocial rehabilitation is the best means of improving social functioning and hence quality of life in people with severe mental illness. The positive results of our study should provide encouragement for further replicative studies. As this was a hospital-based study, replication in community samples is warranted to justify its wider application. Such studies are in progress. If the intervention proves to be generalisable to different settings, there are clear implications for the health of many patients with severe mental illness.
C L I N I C A L I M P L I C A T I O N S
Compliance cherapy is a pragmatic intervention which is acceptable t o patients and easily applicable to the typical busy clinical setting.
Survival of community tenure prior m readmission was improved after the intervention.
The intervention systematically reviews the patient's unique experience of treatment and considers the benefits and drawbacks of treatment for that individual.
L I M I T A T I O N S
B Observer-rated compliance was used rather than laboratory measures or pill counts.
The sample size and drop-out race limit the conclusiveness of the findings.
Blindness of follow-up ratings might be compromised by patients discussing their treatment.
